Transcept Pharma (TSPT) Rejects $4/Share Offer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/18/2024
- Stocks end near flat as investors assess earnings, data
- Netflix Q1 earnings top estimates on blowout subscriber growth
- Taiwan Semi (TSM) Q1 profit beats expectations on AI demand
- Stocks have priced in much of the 2024 optimism - Wells Fargo
- Intuitive Surgiical (ISRG) beats earnings, revenue expectations in Q1
- Hasbro (HAS) Announces Resignation of Cynthia Williams, President of Wizards of the Coast and Hasbro Gaming
- Tritium DCFC Limited (DCFC): Three Australian subsidiaries were determined to be insolvent or likely to become insolvent
- ICZOOM Group (IZM) Discloses Request to Withdraw Registration Statement on Form F-1
- Alaska Airlines flights resume after being grounded over aircraft system issue
- Frontier Communications (FYBR) says third party had gained unauthorized access to portions of its information technology environment
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
- After-hours movers: United Airlines, J.B. Hunt, and more
Transcept Pharma (TSPT) Responds to Request by Retrophin to Acquire Up to 15% Stake
September 30, 2013 8:47 AM EDTTranscept Pharmaceuticals, Inc. (NASDAQ: TSPT) today announced that it had received a communication from Retrophin, Inc. stating that it owns 4.9% of the outstanding common stock of Transcept and seeking permission from the Board of Directors of Transcept to increase its ownership stake up to... More
Transcept Pharma (TSPT) Receives $4.00/Sh Offer from Retrophin
September 18, 2013 4:10 PM EDTRetrophin, Inc. announced that it has made a proposal to the Board of Directors of Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT) to acquire all of the shares of Transcept common stock that Retrophin does not own for $4.00 per share in cash. Retrophins proposal is conditioned on the completion of cursory due diligence and other customary provisions. Retrophins... More
